Aspire Biopharma

ASBP

Market cap $15.7M

ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on protecting the Company's advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients ("APIs") and other substances into the bloodstream, increasing bioavailability and improving speed of onset.

Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference ESTERO, FLORIDA / ACCESS Newswire / October 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced that Kraig Higginson, Interim CEO of Aspire Biopharma will be presenting and participating in 1x1 meetings at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The presentation will feature updates on the company's pipeline progress and key milestones expected throughout the remainder of 2025 and early 2026.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.

Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization Future Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.

BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_stallion/ The influencers have hundreds of thousands of followers across social platforms BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world Sublingual delivery of 50mg of caffeine to the user in less than two minutes BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's E-commerce website ESTERO, FL / ACCESS Newswire / September 17, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed for immediate effect.

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ BOMB™ pre-workout: 50mg caffeine for energy and focus. Boosts performance potential.

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage Lab results showed Aspire's product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025 ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced positive final results from its randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. The final results demonstrated that Aspire's sublingual aspirin product produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA, the active antiplatelet form of aspirin) compared to chewed aspirin tablets (p

According to the NIH , Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths Trial demonstrates dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in clinical trial Aspire's sublingual aspirin was safe and well-tolerated Aspire plans to review clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval ESTERO, FL / ACCESS Newswire / August 18, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced positive top-line data from its recent randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults. Pharmacokinetics is the term that describes the four stages of absorption, distribution, metabolism, and excretion of drugs.

ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_5UneWjXKTOuzgbB4wpeByg One-on-One Meetings Aspire will also host virtual one-on-ones with investors on Wednesday, August 20 and Thursday, August 21, 2025.

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's new E-commerce website ESTERO, FL / ACCESS Newswire / August 13, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its newsublingual pre-workout supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people. BUZZ BOMB™, featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed.